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Abstract
The androgen receptor (AR) has been identified for decades and mediates essential steroid 
functions. Like most of biological molecules, AR functional activities are modulated by post-
translational modifications. This review is focused on the reported activities and significance of 
AR phosphorylation, with particular emphasis on proline-directed serine/threonine 
phosphorylation that occurs predominantly on the receptor. The marked enrichment of AR 
phosphorylation in the most diverse N-terminal domain suggests that targeting AR 
phosphorylation can be synergistic to antagonizing the C-terminal domain by clinical 
antiandrogens.
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Introduction
Androgen receptor (AR)
The identification of steroid receptors (including AR) in the mid-1980s led to the definition 
of a family of ligand-mediated transcription factors that occupy specific chromatic locus for 
gene regulation. The next chapter in advancements is the identification of cofactors 
participating chromatin remodeling, including histone “writers”, “erasers”, and “readers” 
that have continuously been researched up to now. Besides the well-established AR activity 
in mediating transcriptional activation, recent studies further revealed novel functions of AR 
in transcriptional repression, genomic translocation, and mTOR activation [1–6]. Abnormal 
AR activity is associated with various pathogeneses such as male infertility, androgen-
insensitivity syndrome (AIS), polycystic ovarian syndrome (PCOS), spinal and bulbar 
muscular atrophy (SBMA), rheumatoid arthritis, hirsutism, baldness, acne, breast cancer, 
and prostate cancer (PCa).
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The AR molecule is structurally organized into distinct domains: the N-terminal domain 
(NTD) that has a potent activation function 1 (AF-1), DNA-binding domain (DBD), hinge 
domain (H), and ligand-binding domain (LBD) that binds to androgens and has a modest 
activation function 2 (AF-2) (Figure 1A). The AR protein shares highly structural 
similarities in the DBD and LBD with other steroid nuclear receptor family members, such 
as glucocorticoids receptor (GR), mineral corticoid receptor (MR), and progesterone 
receptor (PR). However, its NTD and hinge regions are unique and structurally disordered, 
and share marked diversity among family members. The NTD and hinge domain are also 
less conservative than the DBD and LBD among ARs from different species. Functionally, 
these distinct domains confer activities such as N-to-C interactions, DNA loading, 
antiparallel dimerization, and recruitment of cofactors. The AR proteins are also subjected to 
multiple post-translational modifications such as acetylation, methylation, ubiquitination and 
sumoylation. This review will be focused on AR phosphorylation, with emphasis on proline 
(Pro)-directed phosphorylation.
AR phosphorylation
The identification of AR was immediately followed by the recognition that the receptor is a 
phosphoprotein and that phosphorylated AR is localized to the nucleus upon ligand 
stimulation [7–10]. More extensive studies indicated that AR is synthesized as a single 110 
kDa protein that is rapidly converted into a 112 kDa phosphoprotein in the absence of 
hormone, with constitutive phosphorylation at two Pro-directed serines (Ser650 and Ser94); 
and that androgens can further induce the expression of a 114 kDa isoform which is 
phosphorylated at additional residues and associated with AR nuclear activities [11–13]. The 
distribution of these three isoforms can be attributed to the NTD, in particular the length of 
the outstanding polyglutamine (poly-Q) stretch and the phosphorylation at two adjacent Pro-
directed serines (Ser81 and Ser94) [14].
As shown in table 1, AR has more than 150 theoretically phosphorylable residues, which are 
modestly enriched in the hinge and NTD regions. Interestingly, the AR molecular evolution 
is associated with a decrease in the serines, an increase in the threonines, and a basically 
unchanged number of tyrosines. Furthermore, the Pro-directed Ser (7) and Thr (2) are well 
conserved among species (Table 1). In addition, the human AR also has abundant glycine 
(G, 97), proline (P, 74), and glutamine (Q, 69). Computational calculation indicates that the 
Pro-directed Ser residues are subjected to phosphorylation by Pro-directed Ser/Pro kinase 
(Figure 1B). While the Acid Ser/Pro kinase theoretically covers AR but the C-terminal LBD, 
the Baso Ser/Pro kinase can potentially phosphorylate all four domains (Figure 1B). This 
result is in concordance with an analysis by a distinct program, indicating that the N-
terminal region (NTD-DBD-H; in particular the NTD) is the major phosphorylation locus of 
AR (Figure 1C). Consistently, multiple studies indicated that the NTD is the predominant 
AR phosphorylation region and the phosphorylation occurs mainly on Ser and Thr residues 
[15–17]. Lower phosphorylation frequency identified in DBD and especially the LBD is 
rather due to their highly structural conformation than low percentage of phosphorylable 
residues, considering that phosphorylation occurs mainly on intrinsically unstructured locus 
(Figure 1C and Table 1) [18].
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The enrichment of phosphorylation at NTD implies its function in AR-mediated 
transactivation. Indeed, AR phosphorylation status is strongly correlated with the 
transcriptional function and the agonistic activity of ligands [19]. Consistently, the NTD (the 
major AR phosphorylation region) bears AR activation mediated by the HER2/EGFR and 
IL-6/ MAPK pathways [20,21]; and Aurora-A and Ack1 also activate AR by 
phosphorylating the NTD (Thr282/Ser293 versus Tyr267/Tyr363, respectively) [22,23]. 
Furthermore, AR phosphorylation is involved in AR degradation by the proteasome-
dependent pathway: while phosphorylation at Ser578 promotes AR-Mdm2 (E3 ligase 
murine double minute-2) association and AR degradation, phosphorylation on Tyr (534) 
attenuates AR ubiquitination and interaction with the E3 ligase CHIP (COOH terminus of 
Hsp70-interacting) protein, leading to increased AR expression [24–26]. In addition, AR 
phosphorylation is also linked to additional modifications such as AR acetylation [27].
Proline-directed AR phosphorylation
Despites the scattered reports on AR phosphorylation at various residues, it is well 
documented that the receptor phosphorylation occurs predominantly on the Pro-directed 
serines, as evidenced by the studies based on phosphoamino acid and mass-spec analyses 
(data not shown) [28]. As indicated in figure 1A and table 1, AR totally has seven Pro-
directed serines, with six located at the NTD and one at the hinge region. Functionally, AR 
phosphorylation at Ser308 by cyclin D3/CDK11p58 reduced transcriptional activity [29], 
while the functional significance of S515 phosphorylation appears different between 
exogenous and endogenous studies [13,30,31]. In addition, S424 and S515 phosphorylation 
contributes to AR nuclear localization and functions against receptor aggregation upon 
hormone treatment [32].
Next, we will concentrate on three Pro-directed Ser residues (Ser81, Ser94, and Ser650) that 
are most robustly phosphorylated based on multiple phosphoamino acid and mass-
specanalyses (Figure 2) [12,14]. Although Ser81 is apparently the highest androgen-
stimulated AR phosphorylation residues, this event cannot be readily captured by mass-spec 
due to its particular embedment in the Poly-Q stretch that would compromise the 
fragmentation efficiency during digestion and processing (Figure 2 and 3) [17].
Pro-directed Ser81 phosphorylation
Ser81 is the most stoichiometrically serine residue phosphorylated in response to androgens 
and its phosphorylation occurs with distinct dynamics compared to other AR 
phosphorylation residues [12,17]. The particular activities of Ser81 phosphorylation can be 
attributed to its extraordinary positioning in an unusual polyglutamine (poly-Q) stretch in 
the NTD (Figure 3A). Interestingly, a linear increase in the length of poly-Q is proportional 
to the time of animal divergence, suggesting an association of polyglutamine expansion with 
evolution of the higher primate species [33]. Pathologically, the polymorphic poly-Q is 
causative to certain neurodegenerative diseases, as exemplified by the neuromuscular 
disorder SBMA [34]. In the molecular settings, expansion of the poly-Q track led to 
abnormal AR protein folding, aggregation, and interaction with other proteins, resulting in 
excessive AR degradation and compromised AR transcriptional capacity [35].
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In the prostate cancer (PCa), Ser81 phosphorylation contributes to cell growth, AR-mediated 
transcription, and AR sensitivity to ligand [36–39]. Although transient transfection assay 
yielded little effect of Ser81 phosphorylation on AR-mediated transcription [17,36], studies 
based on PCa and endogenous genes indicated that this phosphorylation had pronounced 
effects on AR nuclear distribution, chromatin binding, and transactivation functions 
[37,39,40]. Consistently, attenuation of AR Ser81 phosphorylation by antagonists for CDK1, 
CDK9, TOPO1 (topoisomerase I) and HER2 led to decreased PCa cell growth and AR 
nuclear functions such as chromatin binding and transcriptional activation [37,39,41,42]. 
Interestingly, AR Ser81 phosphorylation can also function in the PCa epithelial-stromal 
interactions, mediated by the ERK pathway that may directly phosphorylate this residue 
[36,43].
Mechanistically, the initial work from our Lab identified Cdk1 as a Ser81 kinase that can 
phosphorylate Ser81 to stimulate AR nuclear functions [36]. Further studies indicated that 
CDK9 specifically phosphorylate AR at Ser81 upon androgen stimulation, leading to 
productive AR chromatin binding for sustained transcription [37,39]. Consistently, DNA 
binding has been implicated in Ser81 phosphorylation and androgens-induced AR 
localization to the active chromatin may be associated with phosphorylation by specific 
protein kinase occupying the locus [14,44,45]. Together, these findings suggested that 
CDK1-mediated Ser81 phosphorylation may account for the basal Ser81 phosphorylation 
that can initiate AR loading to the chromatin locus, followed by CDK9-mediated 
phosphorylation that is coupled to transcriptional activation (Figure 3B). At molecular 
levels, Ser81 phosphorylation is implicated in AR nuclear distribution and its interaction 
with co-factors, such as CBP (CREB binding protein) and GRIP1 (glucocorticoid receptor-
interacting protein 1) [45]. In addition, a recent report also indicated that Ser81 
phosphorylation mediates the interaction between AR and Pin1, a peptidyl-prolyl cis-trans 
isomerase (PPIase) that specifically isomerizes Pro-directed phospho-Ser/Thr motifs [46].
Pro-directed Ser94 phosphorylation
The Ser94 locates to the C-terminal of the NTD poly-Q track (Figure 3A) and its 
phosphorylation can occur in the absence of ligands [12]. Ser94 together with Ser81 and 
Ser650 are the three Pro-directed residues that are most substantially phosphorylated AR 
residues (Figure 2) [17]. The functional significance of Ser94 phosphorylation is unknown; 
although a bias was found for Ser94 phosphorylated AR distribution in the cytoplasm in the 
absence of androgens [40]. In addition, increased Poly-Q length is associated with enhanced 
Ser94 phosphorylation while transient transfection study has indicated that Ser94 
phosphorylation has minimal effect on AR-mediated activation of exogenous promoters 
[13,17,33]. The Ser94 kinase(s) are also unknown, although CDK1 and CDK5 but not 
CDK9 can be the candidates [36,37]. Considering Ser94 phosphorylation can happen in the 
absence of androgens, it remains to be determined whether this phosphorylation is involved 
in the interaction between AR with the HSP90 complex in the cytoplasm that binds to and 
stabilizes the new-synthesized AR proteins [47].
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Pro-directed Ser650 phosphorylation
The Ser650 in the only Pro-directed serine residue that locates outside of the NTD. It resides 
in the hinge region and centers on the diverse PEST sequence that potentially mediates AR 
protein degradation (Figure 4). The hinge region contains part of the NLS (nuclear 
translocation signal) and regulates AR transactivation and nuclear localization, and is one 
major target site for modifications (acetylation, ubiquitination and methylation) [48,49]. The 
hinge region is also enriched in phosphorylable residues and indeed, mass-spec analysis has 
identified phosphorylation occurring at Ser650 and several adjacent residues (Table 1, 
Figure 4; data not shown). Although transient transfection assays suggested thatS650 
phosphorylation has no or minimal effects on AR functional activities, study based on 
endogenous AR indicated that the stress kinases (JNK (c-Jun N-terminal kinase) and p38) 
regulate Ser 650 phosphorylation and AR nuclear export [13,17,28]. The functions of 
phosphorylation at the adjacent residues (Ser646, Ser647, and Thr652) are unknown (Figure 
4).
Phosphoprotein phosphatases targeting the Pro-directed Ser/Thr residues of AR
The findings that phosphorylated AR is transcriptionally active are essentially consistent 
with the observations that AR dephosphorylation impairs receptor functional nuclear 
activities like ligand binding [50,51]. Consistently, the tumor antigens simian virus 40 small 
t antigen (ST) can mediate PP2A (phosphoprotein phosphatase 2A) binding to AR, leading 
to AR dephosphorylation at five Pro-directed phosphoserines in the NTD and reduction in 
AR activities [51]. Significantly, PP2A activity is attenuated in the androgen-independent 
C4-2 PCa cells as compared with the parental androgen-dependent LNCaP cells [52]. 
Furthermore, PPP2R2C (a PP2A regulatory subunit) was down-regulated in advanced PCa 
to drive castration-resistance [53]. In addition, study from our Lab indicated PP1 
(phosphoprotein phosphatase 1) stimulates AR nuclear functions (in opposite to that of the 
PP2A), mediated by PP1-elicited dephosphorylation of Ser650 in the hinge region [54]. 
These findings are fundamentally in line with the report that caveolin-1 can increase nuclear 
functions of the phosphorylated AR by binding to and inhibiting the PP1 and PP2A [55].
Clinical implications of AR phosphorylation
AR phosphorylation has been extensively implicated in pathogeneses, as exemplified by that 
the development of castration-resistant prostate cancer (CRPC) can be attributed to AR 
phosphorylation at Tyr267 (by the Ack1 pathway) and Ser515/Ser578 (by the EGFR/MAPK 
signaling), respectively [56,57]. The enrichment of AR phosphorylation at the NTD 
indicates one therapeutic strategy is to co-target AR phosphorylation and ligand binding 
functions. Indeed, inhibition of phospho-Ser81 can synergize with anti-androgen to disturb 
CRPC [36,42]. Significantly, a recent systematic study based on screening 673 human 
kinases in PCa cells identified six potential targeting kinases (MAP3K11, DGKD, ICK, CIT, 
GALK2, and PSKH1), and it is important to assess efficacy of antagonizing these candidates 
in combination with clinical antiandrogens [58]. In addition, as one frontier in AR research, 
the receptor phosphorylation has emerged as a potential biomarker in clinical analysis. 
Indeed, breast and prostate cancer studies have been reported based on 
immunohistochemistry (IHC) assays with the phospho-Ser213, Ser515, and Ser650 
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antibodies [31,59–62]. These studies can be further substantiated by sufficient antibody 
validation, such as dose optimization and specific peptide competition analysis.
Conclusions
In summary, altered and amplified phosphorylation can contribute to abnormal AR 
activities, including its ligand-independent activation in diseases including PCa. The AR 
NTD is bestowed with highly selectivity and enriched phosphorylation, providing ample 
opportunities for specific interventions. Targeting NTD phosphorylation (by kinase and 
phosphatase modulators) can be applied in synergy with the LBD antagonists (such as 
antiandrogens) in therapy. Targeting AR phosphorylation is also an option to overcome the 
AR splicing variants that lose the functional ligand binding capacity and are overexpressed 
in advanced PCa [63]. Finally, although AR phosphorylation has been extensively studied in 
receptor activation, its intrinsic connections need to be clarified to AR-mediated 
transrepression and AR non-genomic functions (like mTOR activation).
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Abbreviations
AF-1/2 AR Activation Function 1/2
AIS Androgen-Insensitivity Syndrome
AR Androgen Receptor
CBP CREB Binding Protein
CHIP E3 ligase COOH Terminus of Hsp70-interacting Protein
Co-IP Co-immunoprecipitation
CRPC Castration-resistant Prostate Cancer
DBD AR DNA-binding Domain
DHT Dihydrotestosterone
GR Glucocorticoid Receptor
GRIP1 Glucocorticoid Receptor-Interacting Protein 1
H AR Hinge Domain
IHC Immunohistochemistry
JNK c-Jun N-terminal Kinase
LBD AR Ligand-Binding Domain
Mdm2 E3 Ligase Murine Double Minute-2
MR Mineralocorticoid Receptor
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NLS Nuclear Translocation Signal
NTD AR N-terminal Domain
PCa Prostate Cancer
PCOS Polycystic Ovarian Syndrome
PEST Sequence A Peptide Sequence which is Rich in Proline (P), Glutamic Acid (E), 
Serine (S), and Threonine (T)
Pin1 Peptidyl-Prolyl Cis-Trans Isomerase (PPIase) 1
Poly-Q Polyglutamine
PP1/2A Phosphoprotein Phosphatase 1/2A
PR Progesterone Receptor
SBMA Spinal And Bulbar Muscular Atrophy
ST Tumor Antigens Simian Virus 40 Small T Antigen
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Figure 1. 
Theoretical and computational characterization of human androgen receptor (hAR) 
phosphorylation.(A) hAR amino acid linear organization indicated of structural domains and 
proline(Pro)-directed phosphorylable residues (GenBank: M20132.1); (B) Motif Scan 
Graphic analysis ofhAR subjected to Pro-directed Ser/Pro kinase (Pro_ST_Kin or Pro_), 
Acid Ser/Pro kinase (Acid_ST_Kin or Acid_); and Baso Ser/Pro kinase (Baso_ST_Kin, or 
Baso_) (http://scansite.mit.edu); (C) Phosphorylation analysis of hAR by the DISorder-
enhanced PHOSphorylation predictor (DISPHOS, http://www.ist.temple.edu/DISPHOS) 
program.
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Figure 2. 
A typical mass-spec analysis in AR study. LNCaP cells in androgen-deprived medium were 
treated with DHT (dihydrotestosterone) and AR was harvested by Co-IP (Co-
immunoprecipitation) for mass-spec analysis that was aligned to human AR (GenBank: 
M23263.1). Highlighted are identified phosphorylation corresponding to Ser94 and 
Ser650(GenBank: M20132.1), with Ser424 at lower frequency. Phosphorylation on Ser81 is 
not identified, likely due to its particular location that affects fragmentation during 
processing.
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Figure 3. 
AR linear amino acid sequences in the vicinity of Ser81 and Ser94 residues.(A) Alignment 
of human, chimpanzee, mouse and rat AR with highlighted conserved residues (in red) and 
polyglutamine region (underlined); (B) Schematic drawing indicates that Ser81 
phosphorylation is correlated to AR functional activities.
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Figure 4. 
AR linear amino acid sequences of the hinge domain. Alignment of human, chimpanzee, 
mouse and rat AR with highlighted conserved residues (in red) and PEST sequences 
(underlined). Black arrow heads indicated additional phosphorylation residues (Ser646, 
Ser647, and Thr652) identified in the hinge region by our mass-spec studies (data not 
shown).
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